The first radiosynthesis of [(11)C]AZD8931 as a new potential PET agent for imaging of EGFR, HER2 and HER3 signaling.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2014-09-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2014.07.092PMID 25149507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance

  2014cited by this paper
• ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

  2014cited by this paper
• Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors

  2014cited by this paper
• AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models

  2014cited by this paper
• Synthesis of (Z)-2-((1H-indazol-3-yl)methylene)-6-[¹¹C]methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one as a new potential PET probe for imaging of the enzyme PIM1.

  2013cited by this paper
• Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.

  2013cited by this paper
• [11C]olanzapine, radiosynthesis and lipophilicity of a new potential PET 5-HT2 and D2 receptor radioligand.

  2013cited by this paper
• A high-yield route to synthesize the P-glycoprotein radioligand [11C]N-desmethyl-loperamide and its parent radioligand [11C]loperamide.

  2013cited by this paper
• Progress in structure-based design of EGFR inhibitors.

  2013cited by this paper
• Recent advances in drug design of epidermal growth factor receptor inhibitors.

  2013cited by this paper
• A historical perspective on the specific activity of radiopharmaceuticals: what have we learned in the 35years of the ISRC?

  2013cited by this paper
• Synthesis and evaluation of novel F-18 labeled 4-aminoquinazoline derivatives: potential PET imaging agents for tumor detection.

  2012cited by this paper
• Fully automated synthesis of PET TSPO radioligands [11C]DAA1106 and [18F]FEDAA1106.

  2012cited by this paper
• A new facile synthetic route to [11C]GSK189254, a selective PET radioligand for imaging of CNS histamine H3 receptor.

  2012cited by this paper
• [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers.

  2012cited by this paper
• Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer.

  2011cited by this paper
• Synthesis of [¹¹C]PBR06 and [¹⁸F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO).

  2011cited by this paper
• An improved synthesis of dopamine D2/D3 receptor radioligands [11C]fallypride and [18F]fallypride.

  2010cited by this paper
• Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.

  2010cited by this paper
• Targeting erbB receptors.

  2010cited by this paper
• AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

  2010cited by this paper
• Synthesis of new carbon-11-labeled carboxamide derivatives as potential PET dopamine D3 receptor radioligands.

  2008cited by this paper
• State of art in 11C labelled radiotracers synthesis.

  2008cited by this paper
• The EGF receptor family: spearheading a merger of signaling and therapeutics.

  2007cited by this paper
• ErbB receptors: from oncogenes to targeted cancer therapies.

  2007cited by this paper
• Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib.

  2006cited by this paper
• Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.

  2006cited by this paper
• Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.

  2006cited by this paper
• Purification of carbon-11 PET radiotracers from unlabeled precursors by preparative HPLC and SPE.

  2005cited by this paper
• Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether

  2002cited by this paper
• Studies on new platelet aggregation inhibitors 1. Synthesis of 7-nitro-3,4-dihydroquinoline-2(1H)-one derivatives.

  2001cited by this paper
• Convenient gas phase bromination of [11C]methane and production of [11C]methyl triflate.

  1999cited by this paper
• A simple synthesis of [11C]methyl triflate.

  1992cited by this paper
• Design and synthesis of 2-(arylamino)-4(3H)-quinazolinones as novel inhibitors of rat lens aldose reductase.

  1986cited by this paper
• 356. Synthetic antimalarials. Part XXXI. 2-p-chloroanilino-4-β-diethylaminoethylaminoquinazolines containing various substituents in the quinazoline nucleus

  1948cited by this paper
• Synthetic antimalarials; 2-p-chloroanilino-4-beta-diethylaminoethylaminoquinazolines containing various substituents in the quinazoline nucleus.

  1948cited by this paper

• The Radiolabeled HER3 Targeting Molecules for Tumor Imaging

  2021cites this paper
• Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography.

  2020cites this paper
• Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide

  2018cites this paper
• Synthesis and preliminary biological evaluation of radiolabeled 5-BDBD analogs as new candidate PET radioligands for P2X4 receptor.

  2017cites this paper
• 68Ga labeled Erlotinib: A novel PET probe for imaging EGFR over-expressing tumors.

  2017cites this paper
• NUMBER : W 81 XWH-16-1-0447 TITLE : Quantitative PET Imaging with Novel HER 3-Targeted Peptides Selected by Phage Display to Predict Androgen-Independent Prostate Cancer Progression

  2016cites this paper
• AWARD NUMBER: W81XWH-16-1-0447 TITLE: Quantitative PET Imaging with Novel HER3-Targeted Peptides Selected by Phage Display to Predict Androgen-Independent Prostate Cancer Progression

  2016cites this paper
• Synthesis of a PET tau tracer [(11)C]PBB3 for imaging of Alzheimer's disease.

  2015cites this paper
• Synthesis of [11C]CX-6258 as a new PET tracer for imaging of Pim kinases in cancer.

  2015cites this paper
• Synthesis of [(11)C]GSK1482160 as a new PET agent for targeting P2X(7) receptor.

  2015cites this paper
• Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging

  2015cites this paper